News Search Results
Apr 10, 2025, 05:45 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
April 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: The Gross Law Firm
Apr 10, 2025, 05:45 ET The Gross Law Firm Reminds ICON Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 11, 2025 - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Gross Law Firm
Apr 10, 2025, 02:24 ET Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology
clinical studies showing rapid and extensive drug exposure. About Abera Bioscience Abera Bioscience AB is a Swedish vaccine and biotechnology company founded in 2012, originating from molecular biology research at Vrije Universiteit Amsterdam and Stockholm University.
More news about: Orexo
Apr 10, 2025, 02:21 ET Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology
clinical studies showing rapid and extensive drug exposure. About Abera Bioscience Abera Bioscience AB is a Swedish vaccine and biotechnology company founded in 2012, originating from molecular biology research at Vrije Universiteit Amsterdam and Stockholm University.
More news about: Orexo
Apr 09, 2025, 16:05 ET Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
Incorporated at (877) 750-8310 (toll-free) or (212) 750-5833. About Aerovate Therapeutics, Inc. Aerovate Therapeutics is a biotechnology company that was focused on improving the lives of patients with rare cardiopulmonary disease. For more information, please visit
More news about: Aerovate Therapeutics
Apr 09, 2025, 11:08 ET APHRANEL Global Launch Meeting, in Shanghai China
and promoting the sustainable development of the industry," said the CEO of MOYOM Biotechnology. About Aphranel Aphranel® is a high-profile medical aesthetics brand under Shanghai MOYOM Biotechnology, dedicated to advancing global aesthetics technology through cutting-edge biomaterial
More news about: SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD
Apr 09, 2025, 10:15 ET US Medical Aesthetics Market worth US$16.38 billion by 2030 with 13.6% CAGR | MarketsandMarkets™
aesthetics market is segmented into clinics, hospitals, and medicals spas, beauty centers, and home care settings. In 2025, pharmaceutical and biotechnology firms accounted for the largest share among end users driven by rising demand for minimally invasive and non-invasive aesthetic treatments within
More news about: MarketsandMarkets
Apr 09, 2025, 10:00 ET Auxilium Health Closes Oversubscribed $1.5 Million Funding Round, Secures Additional $275K Grant from the National Science Foundation
University of Akron, the biomaterial platform has already attracted national and international interest from the healthcare and biotechnology sectors. This early traction reflects a growing belief in the technology's potential, positioning the company to rapidly advance partnerships and
More news about: Auxilium Health
Apr 09, 2025, 09:00 ET Visionary Ushered in a Major Reform: The New Board of Directors Ushered in a New Chapter of the Company's High - Tech Industry Development
Hu, and Jinchao Miao, were successfully elected. The new board of directors covers multiple fields such as biotechnology, medical technology research and development, new energy vehicles, education, and finance, which will inject new vitality into the company's development,
More news about: Visionary Holdings Inc.
Apr 09, 2025, 09:00 ET TCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T Cells
April 9, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (OTC: TCBPY) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced receipt of a patent, granted
More news about: TC BioPharm
Apr 09, 2025, 08:45 ET European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Apr 09, 2025, 08:30 ET NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment
April 9, 2025 /PRNewswire/ -- NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced promising new findings from its Phase 2b
More news about: NeuroSense
Apr 09, 2025, 08:10 ET Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Apr 09, 2025, 08:06 ET Kemin Industries ने सह-संस्थापक R.W. Nelson, के निधन पर शोक व्यक्त किया गया।
State of Iowa Economic Impact Award, 1991 में Ernst and Young Entrepreneur Achievement Iowa Award, तथा 2004 में Iowa Biotechnology Association's Entrepreneur Achievement Biotechnology Award भी प्राप्त हुआ था। 2006 में उन्हें Iowa Business Hall of Fame में सम्मिलित किया गया था। R.W. एक सेवक-नेता
More news about: Kemin Industries
Apr 09, 2025, 08:05 ET INOVIO to Present at Upcoming Scientific Conferences
MEETING, Pa., April 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Apr 09, 2025, 08:00 ET Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued
More news about: Anixa Biosciences, Inc.
Apr 09, 2025, 08:00 ET Diakonos Oncology Presents Phase I Analysis of DOC1021 at the 2025 American Academy of Neurology Annual Meeting
Diakonos Oncology, a clinical-stage biotechnology company developing innovative immunotherapies for difficult-to-treat cancers, today announced the successful presentation of an abstract at the
More news about: Diakonos Oncology
Apr 09, 2025, 07:21 ET Oxolife's CEO Agnès Arbat receives prestigious EU Women Innovators Prize
completed a General Management Programme at IESE Business School. She is a guest professor & mentor for the Master's in Pharmaceutical Industry and Biotechnology at UPF and UIC. Oxolife's lead candidate, OXO-001, is a first-in-class non-hormonal drug that acts directly on the endometrium to enhance
More news about: Oxolife
Apr 09, 2025, 07:00 ET Solu Therapeutics Closes $41M Series A Financing and Announces First Patient Dosed in Phase 1 Clinical Trial of STX-0712 in Patients with CMML and Other Advanced Hematologic Malignancies
BOSTON, April 9, 2025 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful
More news about: Solu Therapeutics
Apr 09, 2025, 05:55 ET FRIDAY INVESTOR DEADLINE: ICON PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
insufficient to shield ICON from the adverse effects of a significant market downturn; (iii) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Robbins Geller Rudman & Dowd LLP
Apr 09, 2025, 05:20 ET RoboMarkets expands opportunities for retail clients: new stocks, ETFs, and enhanced trading conditions
Similarweb Ltd.Consumer goods & services: Despegar.com Corp, Gambling.com Group Ltd., Zhihu Inc.Healthcare & Biotechnology: Inari Medical Inc., Surmodics Inc., USANA Health Sciences Inc.Financials: BlackRock Resources & Commodities Strategy Trust,
More news about: RoboMarkets Deutschland GmbH
Apr 09, 2025, 05:18 ET RoboMarkets expands opportunities for retail clients: new stocks, ETFs, and enhanced trading conditions
Ltd.Consumer goods & services: Despegar.com Corp, Gambling.com Group Ltd., Zhihu Inc.Healthcare & Biotechnology: Inari Medical Inc., Surmodics Inc., USANA Health Sciences Inc.Financials: BlackRock Resources & Commodities Strategy Trust,
More news about: RoboMarkets Deutschland GmbH
Apr 09, 2025, 03:30 ET Infinitopes Granted Phase I/IIa Clinical Trial Application Approval to Evaluate Precision Vaccine Targeting Early-Stage Oesophageal Cancer
Safety, Tolerability & Anti-tumour activity) About Infinitopes Infinitopes Ltd is now a clinical stage, integrated cancer biotechnology company supported by Cancer Research UK (CRUK) and the University of Oxford. The Company combines two world leading
More news about: Infinitopes
Apr 08, 2025, 20:23 ET ICLR Deadline: ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit
were insufficient to shield ICON from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: THE ROSEN LAW FIRM, P. A.
Apr 08, 2025, 17:31 ET TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight
next-generation sequencing. The demand for more effective and accessible cancer treatments is fueling innovation in both the pharmaceutical and biotechnology sectors, with numerous new drugs and therapies entering clinical trials and moving toward commercialization. As a result, the oncology market is
More news about: DelveInsight Business Research, LLP